Review: Dipeptidyl peptidase-4 inhibitors do not increase overall adverse events in type 2 diabetes

被引：2
|
作者：
Chatterjee, Saurav [1 ,2 ]
Chatterjee, Sanjay [3 ]
机构：
[1] Brown Univ, Providence, RI 02912 USA
[2] Providence VAMC, Providence, RI USA
[3] Apollo Gleneagles Hosp, Kolkata, W Bengal, India
来源：
ANNALS OF INTERNAL MEDICINE | 2013年 / 158卷 / 08期
关键词：
METAANALYSIS;
D O I：
10.7326/0003-4819-158-8-201304160-02008
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A Review
    Richard, Kathleen R.
    Shelburne, Jamie S.
    Kirk, Julienne K.
    CLINICAL THERAPEUTICS, 2011, 33 (11) : 1609 - 1629
  • [32] Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease
    Baksh, Sheriza N.
    Segal, Jodi B.
    McAdams-DeMarco, Mara
    Kalyani, Rita R.
    Alexander, G. Caleb
    Ehrhardt, Stephan
    PLOS ONE, 2020, 15 (10):
  • [33] Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture
    Driessen, Johanna H. M.
    van Onzenoort, Hein A. W.
    Henry, Ronald M. A.
    Lalmohamed, Arief
    van den Bergh, Joop P.
    Neef, Cees
    Leufkens, Hubert G. M.
    de Vries, Frank
    BONE, 2014, 68 : 124 - 130
  • [34] Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus
    Esaki, Hiroki
    Tachi, Tomoya
    Goto, Chitoshi
    Sugita, Ikuto
    Kanematsu, Yuta
    Yoshida, Aki
    Saito, Kosuke
    Noguchi, Yoshihiro
    Ohno, Yuki
    Aoyama, Satoshi
    Yasuda, Masahiro
    Mizui, Takashi
    Yamamura, Masumi
    Teramachi, Hitomi
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [35] Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety
    Deacon, Carolyn F.
    Holst, Jens J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (15) : 2047 - 2058
  • [36] Dipeptidyl peptidase-4 inhibitors alleviate cognitive dysfunction in type 2 diabetes mellitus
    Meng, Jie
    Yan, Rui
    Zhang, Chen
    Bai, Xueyan
    Yang, Xingsheng
    Yang, Yu
    Feng, Tao
    Liu, Xin
    LIPIDS IN HEALTH AND DISEASE, 2023, 22 (01)
  • [37] Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy
    Cox, Mary Elizabeth
    Rowell, Jennifer
    Corsino, Leonor
    Green, Jennifer B.
    DRUG HEALTHCARE AND PATIENT SAFETY, 2010, 2 : 7 - 19
  • [38] The Role of Dipeptidyl Peptidase-4 Inhibitors in Fat Metabolism in Patients with Type 2 Diabetes
    Ametov, Alexander S.
    DIABETES, 2017, 66 : A627 - A627
  • [39] Dipeptidyl peptidase-4 inhibitors alleviate cognitive dysfunction in type 2 diabetes mellitus
    Jie Meng
    Rui Yan
    Chen Zhang
    Xueyan Bai
    Xingsheng Yang
    Yu Yang
    Tao Feng
    Xin Liu
    Lipids in Health and Disease, 22
  • [40] Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis
    Wu, Shanshan
    Chai, Sanbao
    Yang, Jun
    Cai, Ting
    Xu, Yang
    Yang, Zhirong
    Zhang, Yuan
    Ji, Linong
    Sun, Feng
    Zhan, Siyan
    CLINICAL THERAPEUTICS, 2017, 39 (09) : 1780 - 1789
12345